Ameriprise
FULC icon

Ameriprise’s Fulcrum Therapeutics FULC Stock Holding History

Ameriprise’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,675
Closed -$1.14M – 4123
2025
Q4 		$1.14M Sell
100,675
-23,991
-19% -$244K ﹤0.01% 3275
2025
Q3 		$1.15M Buy
+124,666
New +$902K ﹤0.01% 3291
2023
Q1 		– Sell
-20,994
Closed -$153K – 3976
2022
Q4 		$153K Buy
20,994
+330
+2% +$2.15K ﹤0.01% 3752
2022
Q3 		$167K Hold
20,664
– – ﹤0.01% 3739
2022
Q2 		$101K Buy
+20,664
New +$202K ﹤0.01% 3778

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ameriprise's FULC Position: Q1 2026 in Review

Ameriprise sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 100,675 shares — an estimated $1.14M sold.

Ameriprise first reported a position in FULC in Q2 2022 and held it in 5 quarters. The position peaked at $1.15M in Q3 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Ameriprise reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 100,675 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.14M.
  • Ameriprise first reported a position in Fulcrum Therapeutics in Q2 2022 and held it in 5 quarters.
  • Ameriprise's Fulcrum Therapeutics position peaked at $1.15M in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.